Option 3, ideally Big Pharma do all the heavy lifting, speeds up the process minimise exposure to risk.
Similar deal structure to current US/Acadia deal with royalties and milestones would be very rewarding for Neu, with Trof asset and NZ-2591 if successful Neu could be looking at revenue annually approx A$1B (MST forecast $$ from Trof FY24 $165m for FY25 x 5= $825m for NZ-2591)
Quickest way for all involved patients and shareholders, possibly hit the market FY25
With A$1b pre tax revenue for Neu, dividends will happen along with hopefully healthy share price with EPS $7.75
Ann: Q4 2021 quarterly activity and cash flow report, page-36
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.85 |
Change
-0.110(0.85%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.53 | $6.559M | 511.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1657 | $12.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 6303 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |